Predictive Oncology Develops 3D Organoid Models Exclusively For Labcorp, Including Human And Rat Model

-0.55%

+1.78%

Laboratory Corporation of America Holdings

0.00

PREDICTIVE ONCOLOGY INC

POAI

0.00

Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models exclusively for Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services.

As part of an ongoing agreement, Predictive Oncology recently developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, including a human and rat model. Both models represent the liver microenvironment and can be used for the evaluation of both drug metabolism and liver toxicity related to drugs.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.